2:43 PM
 | 
Jul 28, 2017
 |  BioCentury  |  Emerging Company Profile

Microbiotal reverse-engineering

How Finch is moving from fecal microbiotal transplant to oral therapy

Finch Therapeutics Inc. is developing an oral alternative to fecal microbial transplant that it believes entails less biology risk than more advanced oral candidates, with more targeted delivery than full microbiome transplants delivered via enema.

Lead candidate FIN-403 is slated to enter Phase II testing this year to treat recurrent Clostridium difficile infection. According to co-founder and CEO Mark Smith, the therapy delivers nearly all of the microbial communities present in donor microbiomes that have successfully prevented recurrence of infection in the clinic.

The company identifies successful donors via a strategic relationship with OpenBiome, a non-profit stool sample biobank and fecal microbiota transplant (FMT) provider that Smith founded in 2012. Finch sponsors the non-profit’s clinical trials in exchange for access to the data.

“We take a top-down approach, starting with something that works,” Smith told BioCentury. “Other approaches are more bottom-up, where they say we think we understand the biology, and we’re going after this mechanism.”

FIN-403 also uses a dual-release oral delivery technology licensed from Intract...

Read the full 827 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >